Suspension of trading

Bellicum Pharmaceuticals, Inc. Stock

Stocks

BPXA

US0794814048

Biotechnology & Medical Research

OTC Markets Traded
Delayed Börse Stuttgart 5-day change 1st Jan Change
- EUR -.--% Intraday chart for Bellicum Pharmaceuticals, Inc. -2.31% -53.99%
3 years 0
Extreme 0
0.19
5 years 0
Extreme 0
0.19
10 years 0
Extreme 0
0.19
Manager TitleAgeSince
Chief Executive Officer 66 23/02/2024
Chief Executive Officer 57 31/01/2017
Director TitleAgeSince
Director/Board Member 57 -
Director/Board Member - -
Date Insider Type Main position Quantity % Market Cap.
11/22/23 A
Baker Bros. Advisors LP
OptionCompany 4,232,698 44.5721%
1/3/23 A Fiscal year

Chairman

121,452 1.4100%
1/3/23 A Fiscal year

Director

74,739 0.8677%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-2.31% - - 822K
-3.42%+4.90%+61.15%+87.70% 55.98B
-1.63%-3.38%+50.37%+68.65% 53.69B
-2.14%-9.13%+2.74%+421.65% 23.29B
-0.47%-1.53%-18.61%-15.41% 23.15B
-5.95%-2.58%+30.67%-9.47% 20.58B
-2.34%-1.02%+30.20%-31.14% 17.76B
-4.55%-1.95%+192.65%+349.58% 16.09B
-6.91%-5.83%+26.53%+644.30% 15.93B
+0.23%-2.49%+24.26%+187.16% 14B
Average -2.72%-0.62%+44.44%+189.22% 24.05B
Weighted average by Cap. -2.85%-0.88%+44.87%+148.95%

Financials

2021 2022
Net sales 6.2M 5.42M 5.01M 4.6M 8.7M 597M 8.86M 59.77M 23.48M 292M 23.28M 22.77M 1.01B 1.5M 1.31M 1.21M 1.11M 2.11M 145M 2.14M 14.46M 5.68M 70.58M 5.63M 5.51M 244M
Net income -9.7M -8.48M -7.85M -7.2M -13.62M -935M -13.86M -93.56M -36.75M -457M -36.45M -35.65M -1.58B -24.97M -21.83M -20.19M -18.52M -35.06M -2.41B -35.67M -241M -94.58M -1.18B -93.78M -91.72M -4.06B
Net Debt - -
Logo Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals Inc is a United States-based company. The Company operates as a biopharmaceutical company focused on discovering and developing cellular immunotherapies for various forms of cancer.
Employees
13
  1. Stock Market
  2. Stocks
  3. BPXA Stock